Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 16, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory disclosure of share transactions and does not contain financial performance data.
Material Changes
The material change reported is a transfer of 7,622 Ordinary Shares from the GlaxoSmithKline Employee Trust ("the GSK Trust") to participants in the SmithKline Beecham Employee Share Option Plan 1991. This transaction occurred on June 14, 2006, and was advised to the company on June 16, 2006.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The transaction is noted as being in accordance with Disclosure Rule 3.1.4R(1)(b). The GSK Trust is identified as a discretionary trust where all current and former employees are potential beneficiaries.
Key Facts for Investor Verification
- Transaction Date: June 14, 2006.
- Shares Transferred: 7,622 Ordinary Shares.
- Parties Involved: Abacus (GSK) Trustees Limited (Trustee) to participants of the SmithKline Beecham Employee Share Option Plan 1991.
- Director Interest: Directors Dr J-P Garnier, Dr M M Slaoui, and Mr J S Heslop hold interests in the GSK Trust in the same capacity as other employees.
- Financial Data: No financial metrics are included in this specific filing.